IMA Group has acquired ProSys Group for an undisclosed amount. The acquisition marks a strategic expansion for IMA Group into specialized isolator technology and advanced sampling systems within the bio-pharmaceutical market.
ProSys Group is a leading provider of isolator technology and sampling systems, primarily serving the bio-pharmaceutical sector. The company designs and manufactures ‘Engineered to Order’ (EtO) isolators for aseptic processing in ISO5 environments and for the management of highly potent compound handling to OEB5 & 6 levels. Additionally, ProSys Group develops liquid, gas, and powder sampling systems for various industrial applications, including toxic environments and high-pressure, viscous, or low-volume sampling needs. Since its founding in 1997, ProSys has built its reputation on 'Customer Intimacy,' design flexibility, equipment quality, and delivery assurance, operating globally with local technical and after-sales service support for clients across Clinical, R&D, Manufacturing, and Consultancy sectors.
This acquisition is expected to significantly strengthen IMA Group's capabilities and offerings in the bio-pharmaceutical industry. ProSys Group's specialized expertise in containment and sampling solutions complements IMA Group's existing portfolio, enabling the combined entity to provide more comprehensive and integrated solutions to its global customer base. The addition of ProSys Group's advanced isolator technology and sampling systems will enhance IMA Group's ability to address critical demands in aseptic processing and the safe handling of highly potent compounds.
The integration of ProSys Group into IMA Group is anticipated to create substantial synergies, leveraging ProSys's technological prowess and global service network. This strategic move aims to meet the evolving needs of the bio-pharmaceutical market for advanced, high-quality containment and sampling solutions, positioning the combined entity for continued innovation and expanded market reach.